entertainment -WSS

entertainment

author：hotspot 2025-09-30 18:43:28 - browse：536

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Private equity could exacerbate cardiology's overuse problem, experts fear

focus

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

What don’t we know about an Alzheimer’s drug side effect?

30 years of 'Listening to Prozac'

As biotech industry slumps, bioscience job market is upside down

PEPFAR is under serious threat — and so is global health

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

hotspot

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

What to do when lifesaving products contribute to climate change

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Medicare proposal to cover medical devices draws a mixed reaction

How housing is health care on Long Island

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Popular nasal decongestant doesn't actually relieve congestion

Novavax promises a turnaround & Lilly roils the obesity market

FDA proposes changes to key medical devices approval pathway

focus

CDC director unscathed in first congressional testimony

FDA panel endorses Alnylam’s heart drug — after picking it apart

Diverse clinical trials: Why aren’t we there yet?

What to do when lifesaving products contribute to climate change

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

How to make the FDA’s new prescription one

Wikipedia

focus

Wikipedia

hotspot